Assembly Biosciences is a clinical stage biotechnology company which develops oral therapeutics for the treatment of hepatitis B virus infection and novel class of oral synthetic live biotherapeutics. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The Company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions, and a patent pending delivery system, GEMICEL.

Type
Public
HQ
Carmel, US
Founded
2005
Size (employees)
69 (est)+36%
Assembly Biosciences was founded in 2005 and is headquartered in Carmel, US
Report incorrect company information

Assembly Biosciences Office Locations

Assembly Biosciences has offices in Carmel and San Francisco
Carmel, US (HQ)
310 11711 N Meridian St
San Francisco, US
409 Illinois St
Show all (2)
Report incorrect company information

Assembly Biosciences Financials and Metrics

Assembly Biosciences Revenue

USD

Net income (Q1, 2018)

(16.2 m)

EBIT (Q1, 2018)

(16.7 m)

Market capitalization (18-Jul-2018)

1.1 b

Closing share price (18-Jul-2018)

42.8

Cash (31-Mar-2018)

66.9 m
Assembly Biosciences's current market capitalization is $1.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

12.2 m17 m

R&D expense

33.1 m44.2 m

Operating expense total

45.3 m61.2 m

EBIT

(98.2 m)(24 m)(29.7 m)(45.3 m)(52.2 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

1.4 m7.4 m3.4 m2.5 m2.5 m3.2 m2.9 m2.8 m4 m3.8 m5.7 m

R&D expense

1.1 m3.7 m3.8 m4.7 m4.6 m8.1 m7.5 m8.8 m10.6 m12.1 m14.5 m

Operating expense total

2.5 m11.1 m7.2 m7.2 m7.1 m11.3 m10.5 m11.7 m14.6 m15.9 m20.2 m

EBIT

(2.5 m)(11.1 m)(7.2 m)(7.2 m)(7.1 m)(11.3 m)(10.5 m)(11.7 m)(13.9 m)(13.6 m)(16.7 m)
Annual
usdY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016FY, 2017

Cash

81.3 k14.6 m37 m20.5 m27.1 m29.1 m27.1 m28.6 m82 m

Accounts Receivable

Inventories

611.2 k

Current Assets

27.1 m29.2 m68.4 m53.6 m123.1 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

21.3 m17.9 m96.1 m53.5 m36.4 m20.4 m20.3 m23.8 m70.8 m39.5 m66.9 m

Accounts Receivable

1.1 m

Current Assets

21.7 m18.1 m96.3 m71.3 m66.5 m59.1 m64.1 m59.3 m92.2 m77.7 m113.2 m

PP&E

173.2 k174 k156.5 k132.2 k113.7 k128.5 k182.8 k131.9 k731.5 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(19.4 m)(23.8 m)(28.5 m)(44.3 m)(42.8 m)

Depreciation and Amortization

6.2 k11 k65 k80.3 k219.2 k

Inventories

93.1 k

Accounts Payable

(107.4 k)(2.5 m)456.1 k1 m(244.2 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(2.5 m)(11 m)(7.1 m)(6.9 m)(6.6 m)(11 m)(10.2 m)(11.6 m)(13.9 m)(27.5 m)(16.2 m)

Depreciation and Amortization

168.1 k

Accounts Payable

2.3 m1.4 m1.4 m1 m1.3 m1.3 m1.5 m2.3 m2.4 m3.8 m1.9 m248.9 k

Cash From Operating Activities

(15.5 m)
USDY, 2018

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information

Assembly Biosciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Assembly Biosciences Company Life and Culture

Report incorrect company information